Scarica l'app Stockscreener
0.3075
3.48%
-0.0111
Dopo l'orario di chiusura:
.30
-0.0075
-2.44%
Precedente Chiudi:
$0.3186
Aprire:
$0.3119
Volume 24 ore:
577.96K
Relative Volume:
0.09
Capitalizzazione di mercato:
$4.52M
Reddito:
$5.07M
Utile/perdita netta:
$-10.18M
Rapporto P/E:
-0.0729
EPS:
-4.2178
Flusso di cassa netto:
$-7.93M
1 W Prestazione:
+3.78%
1M Prestazione:
-25.76%
6M Prestazione:
-82.63%
1 anno Prestazione:
-86.02%
Intervallo 1D:
$0.2951
$0.3195
Intervallo di 1 settimana:
$0.271
$0.3231
Portata 52W:
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Nome
Ensysce Biosciences Inc
Settore
Industria
Telefono
(858) 263-4196
Indirizzo
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.3075 | 4.68M | 5.07M | -10.18M | -7.93M | -4.2178 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ensysce Biosciences Inc Borsa (ENSC) Ultime notizie
Ensysce Faces New Nasdaq Issue as Deadline Nears - Bez Kabli
Ensysce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Compliance Update - Minichart
Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule - Investing.com
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Ensysce Biosciences (NASDAQ: ENSC) warned on Nasdaq equity listing rule - Stock Titan
Ensysce Biosciences : Corporate Overview - marketscreener.com
ENSC Advancing Testing and Expanding Potential - Yahoo Finance
Ensysce Biosciences (ENSC) Rallies +0.54% as Bulls Target $0.29 2026-05-18OBV Divergence - Newser
Press Releases about Ensysce Biosciences, Inc.Common Stock - The Chronicle-Journal
Ensysce Biosciences, Inc.Common Stock (Nasdaq:ENSC) Stock Quote - The Chronicle-Journal
Ensysce Biosciences (ENSC) price target decreased by 34.79% to 16.78 - MSN
Ensysce Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ensysce biosciences launches formal review of strategic alternativesSEC filing - marketscreener.com
Ensysce Biosciences Launches Formal Review Of Strategic AlternativesSEC Filing - TradingView
Ensysce Biosciences : Earnings Release Q1 2026 - marketscreener.com
ENSC: Clinical milestones and new financing highlight Q1 2026 amid ongoing R&D-driven losses - TradingView
Wider Q1 loss leaves Ensysce (NASDAQ: ENSC) with limited cash runway - Stock Titan
Ensysce Biosciences (ENSC) posts Q1 2026 loss, cash squeeze and strategic review - Stock Titan
This biotech is testing an opioid designed to limit overdose risk - Stock Titan
ENSC Q1'26 Earnings: EPS estimate is (0.73) USD - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Nasdaq most active stocks: - MSN
TradingKey - TradingKey
Ensysce receives Taiwan patent for overdose protection technology - Investing.com UK
Ensysce receives Taiwan patent for overdose protection technology By Investing.com - Investing.com South Africa
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Corsicana Daily Sun
Opioid overdose-protection tech MPAR gets Taiwan patent to 2042 - Stock Titan
Sold 🍀🤞🏻 - Moomoo
$Ensysce Biosciences (ENSC.US)$ something in the milk aint clean…LG - Moomoo
MSN Money - MSN
Ensysce Biosciences Inc expected to post a loss of 73 cents a shareEarnings Preview - TradingView
Why are smart money investors paying attention to Ensysce Biosciences (ENSC)? (Tumbles Hard) 2026-05-08Wall Street Picks - Newser
Ensysce CEO outlines abuse-resistant opioid approach in Amsterdam - Stock Titan
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam - Corsicana Daily Sun
What Ensysce Biosciences (ENSC) disclosed about cash conversion | Q4 2025: Earnings Beat EstimatesFree Stock Community - Newser
ENSC Ensysce Biosciences reports narrower Q4 2025 loss than estimates, shares climb after earnings release.Senior Analyst Forecasts - newser.com
ENSC Should I Buy - Intellectia AI
ENSC - Finviz
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences (ENSC) Sector Trends | Q4 2025: EPS Beats ForecastsCommunity Chart Signals - UBND thành phố Hải Phòng
Ensysce receives IRB approval for final opioid overdose study phase By Investing.com - Investing.com India
Ensysce Biosciences Secures IRB Approval for Final Phase of Clinical Study - National Today
Ensysce receives IRB approval for final opioid overdose study phase - Investing.com
Opioid with built-in overdose safeguard enters final study stage - Stock Titan
[EFFECT] Ensysce Biosciences, Inc. SEC Filing - Stock Titan
Price Action: Will Ensysce Biosciences Inc benefit from geopolitical trendsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Bull Run: Is Ensysce Biosciences Inc subject to activist investor interest2026 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Ensysce Biosciences Inc Azioni (ENSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):